Clinical Trials Logo

Benign Neoplasm clinical trials

View clinical trials related to Benign Neoplasm.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06174532 Recruiting - Benign Neoplasm Clinical Trials

Virtual Surgical Planning in Mandibular Segmental Resection

Start date: December 27, 2023
Phase: N/A
Study type: Interventional

Purpose: Odontogenic tumors, predominantly affecting the mandibular region, pose significant challenges in terms of treatment planning, particularly when requiring segmental mandibular resection. This study aims to evaluate the effectiveness of virtual planning and 3D modeling in comparison to traditional surgical methods for treating mandibular odontogenic tumors, focusing on aspects such as accuracy, clinical outcomes, and patient quality of life. Method: The study is designed as a two-phase investigation. Phase 1 involves in vitro research to create high-precision 3D models and surgical support instruments. Phase 2 consists of a clinical trial with two groups: the Virtual Surgery Group using pre-bent reconstruction plates, 3D mandibular models and surgical guides and the Conventional Surgery Group. Data collection includes assessing model accuracy, comparing clinical outcomes, analyzing postoperative CT scans, and evaluating patient quality of life. Expected Results: Investigators anticipate that the virtual planning and 3D modeling approach will yield more accurate surgical procedures, improved postoperative outcomes, and enhanced patient quality of life compared to traditional methods. This is expected to be particularly beneficial in maintaining the stability of the condyle at the postoperative site, reducing complications related to mandibular function, and potentially reducing the need for additional surgeries. Conclusions: If the investigators study demonstrates the superiority of virtual planning and 3D modeling in treating mandibular odontogenic tumors, it could significantly impact the field of oral and maxillofacial surgery by offering a more precise and effective treatment approach. This could ultimately lead to improved patient outcomes and a reduction in the challenges associated with these complex surgical procedures.

NCT ID: NCT05726136 Recruiting - Colorectal Cancer Clinical Trials

Fluid Challenge and Plasma Volume, During Surgery

FC-VE
Start date: October 23, 2023
Phase: Phase 4
Study type: Interventional

A short bolus infusion of fluid, called "fluid challenge" is commonly recommended for fluid treatment during longer surgery. However a prolonged increase of the blood volume is a prerequisite to recommend the technique. The purpose with the study is to examine the plasma expanding effect of three different fluid challenge strategies (acetated Ringers 4 ml/kg body weight, albumin 5% 4 ml/kg body weight or albumin 20% 1 ml/kg body weight), using hemoglobin as a dilution indicator.

NCT ID: NCT05082441 Recruiting - Benign Neoplasm Clinical Trials

Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection

Start date: September 1, 2020
Phase: Phase 4
Study type: Interventional

Liposomal bupivacaine (Exparel) has been used as an adjunct to pain management in the perioperative setting. However, the efficacy of the drug has not bewen studied in patients with benign soft tissue tumor resections. The goal of the study is to see if Exparel controls pain and improves functional outcomes for patients after these procedures compared to the current standard Bupivacaine HCL.

NCT ID: NCT04752137 Recruiting - Malignant Neoplasm Clinical Trials

Intraoperative Tumor Margin Identification With ICG Dye Imaging

Start date: May 25, 2022
Phase: Phase 2
Study type: Interventional

In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.